CA2400638A1 - 7 proteines humaines ovariennes et proteines associees au cancer des ovaires - Google Patents
7 proteines humaines ovariennes et proteines associees au cancer des ovaires Download PDFInfo
- Publication number
- CA2400638A1 CA2400638A1 CA002400638A CA2400638A CA2400638A1 CA 2400638 A1 CA2400638 A1 CA 2400638A1 CA 002400638 A CA002400638 A CA 002400638A CA 2400638 A CA2400638 A CA 2400638A CA 2400638 A1 CA2400638 A1 CA 2400638A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- seq
- polypeptides
- sequence
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne de nouveaux polynucléotides ovariens ou associés au cancer des ovaires et les polypeptides codés par ces polynucléotides désignés collectivement <= antigènes du cancer des ovaires >=, et l'utilisation de ces antigènes ovariens afin de détecter des troubles du système reproductif, en particulier, la présence d'un cancer des ovaires ou de métastases du cancer des ovaires. Elle concerne des antigènes du cancer des ovaires, ainsi que des vecteurs, des cellules hôtes, des anticorps dirigés contre des antigènes du cancer des ovaires, les procédés de recombinaison et les procédés de synthèse servant à les préparer. Elle concerne également des procédés diagnostiques servant à détecter, traiter, prévenir et/ou pronostiquer des troubles associés aux ovaires, y compris le cancer des ovaires, et des procédés thérapeutiques servant à traiter ces troubles. Elle concerne, de plus, des procédés de criblage servant à identifier des agonistes et des antagonistes de ces antigènes du cancer des ovaires. Elle concerne également l'inhibition de la production et du fonctionnement de ces polypeptides.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19007600P | 2000-03-17 | 2000-03-17 | |
| US60/190,076 | 2000-03-17 | ||
| US22700900P | 2000-08-23 | 2000-08-23 | |
| US60/227,009 | 2000-08-23 | ||
| PCT/US2001/008585 WO2001070804A1 (fr) | 2000-03-17 | 2001-03-16 | 7 proteines humaines ovariennes et proteines associees au cancer des ovaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2400638A1 true CA2400638A1 (fr) | 2001-09-27 |
Family
ID=26885755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002400638A Abandoned CA2400638A1 (fr) | 2000-03-17 | 2001-03-16 | 7 proteines humaines ovariennes et proteines associees au cancer des ovaires |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1268541A1 (fr) |
| JP (1) | JP2003527851A (fr) |
| AU (1) | AU2001252917A1 (fr) |
| CA (1) | CA2400638A1 (fr) |
| WO (1) | WO2001070804A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044813A1 (en) * | 2001-03-30 | 2003-03-06 | Old Lloyd J. | Cancer-testis antigens |
| CA2443617C (fr) * | 2001-04-17 | 2013-12-10 | The Board Of Trustees Of The University Of Arkansas | Sequences repetees du gene ca125 et leurs utilisations dans des interventions diagnostiques et therapeutiques |
| US7309760B2 (en) | 2001-04-17 | 2007-12-18 | The Board Of Trustees Of The University Of Arkansas | Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions |
| WO2004035537A2 (fr) | 2002-10-16 | 2004-04-29 | Euro-Celtique S.A. | Anticorps se fixant sur des polypeptides ca 125/0722p associes a des cellules et leurs procedes d'utilisation |
| CA2515708A1 (fr) * | 2003-02-11 | 2004-08-26 | Transkaryotic Therapies, Inc. | Diagnostic et traitement de la deficience en sulfatase multiple et d'autres deficiences en sulfatase |
| EP2056110A1 (fr) * | 2007-10-31 | 2009-05-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Biomarqueur pour prédire une réponse à un traitement par un anti-TNF-alpha |
| US20160145589A1 (en) | 2011-06-24 | 2016-05-26 | Green Cross Corporation | Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof |
| KR101380740B1 (ko) | 2012-06-29 | 2014-04-11 | 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 | 이듀로네이트-2-설파타제의 정제 |
| US9150841B2 (en) | 2012-06-29 | 2015-10-06 | Shire Human Genetic Therapies, Inc. | Cells for producing recombinant iduronate-2-sulfatase |
| GB2543728B (en) | 2014-08-12 | 2019-04-17 | Nextgen Jane Inc | Medical kit and method for processing a biological sample |
| WO2017180909A1 (fr) | 2016-04-13 | 2017-10-19 | Nextgen Jane, Inc. | Dispositifs, systèmes et procédés de collecte et de conservation d'échantillon |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
-
2001
- 2001-03-16 EP EP01926376A patent/EP1268541A1/fr not_active Withdrawn
- 2001-03-16 AU AU2001252917A patent/AU2001252917A1/en not_active Abandoned
- 2001-03-16 CA CA002400638A patent/CA2400638A1/fr not_active Abandoned
- 2001-03-16 JP JP2001569004A patent/JP2003527851A/ja not_active Withdrawn
- 2001-03-16 WO PCT/US2001/008585 patent/WO2001070804A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1268541A1 (fr) | 2003-01-02 |
| JP2003527851A (ja) | 2003-09-24 |
| WO2001070804A1 (fr) | 2001-09-27 |
| AU2001252917A1 (en) | 2001-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7368531B2 (en) | Human secreted proteins | |
| US7968689B2 (en) | Antibodies to HSDEK49 polypeptides | |
| US20020081659A1 (en) | Nucleic acids, proteins and antibodies | |
| US20030059875A1 (en) | Nucleic acids, proteins, and antibodies | |
| US20030040617A9 (en) | Nucleic acids, proteins and antibodies | |
| US20020039764A1 (en) | Nucleic, acids, proteins, and antibodies | |
| US20030064072A9 (en) | Nucleic acids, proteins and antibodies | |
| CA2392757A1 (fr) | Acides nucleiques, proteines et anticorps | |
| CA2395811A1 (fr) | Acides nucleiques, proteines, et anticorps | |
| CA2395525A1 (fr) | Polynucleotides, polypeptides, et anticorps de transferrine | |
| US20020151681A1 (en) | Nucleic acids, proteins and antibodies | |
| CA2394753A1 (fr) | Polynucleotides et polypeptides de la protein thyrosine phosphatase humaine, et anticorps | |
| CA2403508A1 (fr) | Polynucleotides, polypeptides et anticorps matriciels extracellulaires | |
| CA2398227A1 (fr) | 17 proteines secretees humaines | |
| CA2400638A1 (fr) | 7 proteines humaines ovariennes et proteines associees au cancer des ovaires | |
| US20060073561A1 (en) | 157 human secreted proteins | |
| US20030054379A1 (en) | Nucleic acids, proteins, and antibodies | |
| CA2391594A1 (fr) | Anticorps, polypeptides et polynucleotides contenant un domaine dit en feuille de trefle | |
| CA2386641A1 (fr) | 32 proteines humaines secretees | |
| CA2382729A1 (fr) | 29 proteines associees au cancer humain | |
| US20040010121A1 (en) | 7 Human ovarian and ovarian cancer associated proteins | |
| CA2399921A1 (fr) | Polynucleotides et polypeptides de la proteine tyrosine phosphatase, et anticorps | |
| US20020164692A1 (en) | Immune system-related polynucleotides, polypeptides, and antibodies | |
| CA2418676A1 (fr) | 21 proteines humaines secretees | |
| CA2423559A1 (fr) | Proteines secretees humaines 22 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |